Loading
institutionsInstitution
Institut Curie
Founded by Marie Curie; a leader in breast cancer, radiotherapy, and proton therapy.
Overview
Institut Curie in Paris was founded by Marie Curie and is a comprehensive cancer centre and research institute, ranked twenty-first in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. Its strengths are breast cancer and the biology of triple-negative disease, radiotherapy and the Orsay proton centre, uveal melanoma and paediatric oncology, with François-Clément Bidard, Olivier Delattre, Christophe Le Tourneau, Eliane Piaggio and Sergio Roman-Roman among its scientists. OnCo links it to the tumour microenvironment pathway, to the question of what holds T cells at the tumour border, and to Institut National du Cancer, Fondation ARC and the LYSA lymphoma group. How to turn microenvironment biology into treatments is the problem its immunology work chases. Its breast and proton programmes are the ones most readers want.
Location
Paris, FR
Type
cancer center
Website
Newsweek 2026 oncology rank
#21
OnCo score
#35 · 69 points (39 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Institut Curie, including child institutions. 1,044 works · 15,238 citations · 72% open access · 15% clinical trials · 1% reviews.
Oncology works per year
2142022
2262023
2282024
2332025
1432026
Most works
- Nicolas M Girard53 works
- Anne Vincent‐Salomon47 works
- Steven Le Gouill46 works
- Roch Houot44 works
- Christophe Le Tourneau44 works
- Delphine Loirat36 works
- Paul Henri Cottu35 works
- Olivier Trédan34 works
- Emmanuel Bachy34 works
- Anne‐Sophie Hamy33 works
Most cited
- Breast cancer
- Proton therapy
- Uveal melanoma
Christophe Le Tourneau
Head of Early Phase Trials (D3i), Institut Curie; Professor, Paris-Saclay
Early-phase trialsHead and neck cancerPrecision medicine methodology
Led SHIVA, the first randomised trial of genomics-matched therapy, and heads Institut Curie's early trials unit.
Eliane Piaggio
Team Leader, Translational Immunotherapy, Institut Curie
Tumour immunologyRegulatory T cellsImmunotherapy biomarkers
Eliane Piaggio is an immunologist studying regulatory T cells and immune profiling to guide immunotherapy.
François-Clément Bidard
Head of Medical Oncology, Institut Curie; Professor, UVSQ Paris-Saclay
Breast cancerCirculating tumour DNAEndocrine therapy
Led PADA-1, the first trial to switch endocrine therapy on a rising ESR1 mutation in blood.
Olivier Delattre
Director, Research Center, Institut Curie; Head, Genetics and Biology of Cancers
Paediatric sarcomaEwing sarcoma geneticsCancer genomics
Olivier Delattre discovered the EWS-FLI1 fusion that defines Ewing sarcoma.
Sergio Roman-Roman
Director of Translational Research, Institut Curie
Translational researchUveal melanomaPreclinical models
Directs the translational research department that developed models and targets for uveal melanoma.
Steven Le Gouill
Director, Institut Curie Hospital Group; haematologist
LymphomaMantle cell lymphomaHospital leadership
Steven Le Gouill is a lymphoma specialist who leads the Institut Curie hospitals.
Sylvie Bonvalot
Surgical oncologist, Institut Curie, Paris
Retroperitoneal sarcomaSarcoma surgeryPreoperative radiotherapy
Paris surgeon who championed compartmental resection for retroperitoneal sarcoma and led STRASS, the trial that showed preoperative radiotherapy does not improve abdominal recurrence-free survival overall.
observationalLancet 20181,753 citations
International validation of the consensus Immunoscore for the classification of colon cancer
It is the strongest evidence that an immune measurement should sit beside TNM staging in colon cancer, and the basis for using it to decide adjuvant chemotherapy in stage II disease, which is where the argument is now.
translationalImmunity 2016837 citations
Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability
It explains the good prognosis of mismatch repair deficient disease as an immune effect rather than a repair effect, and identifies the microsatellite-stable tumours with an immune programme as the group worth trying immunotherapy in.
Similar pages
- InstitutionGustave Roussy
Shares Fondation ARC pour la recherche sur le cancer, Institut Pasteur, Institut National du Cancer, Haute Autorité de Santé.
- InstitutionCentre Antoine Lacassagne
Shares UNICANCER, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, Melanoma.
- InstitutionLigue nationale contre le cancer
Shares Fondation ARC pour la recherche sur le cancer, UNICANCER.
- CompanyLeo Cancer Care
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Proton therapy.
- CompanyP-Cure
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Proton therapy.
- CompanyMevion Medical Systems
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Proton therapy.
- TechnologyProton arc therapy
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Proton therapy.
- PersonSuzette Delaloge
Shares Institut National du Cancer, Triple-negative breast cancer (TNBC).